These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17117298)

  • 1. Bisphosphonates.
    McClung M
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):735-44. PubMed ID: 17117298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.
    McClung MR
    Bone; 1996 Nov; 19(5 Suppl):195S-198S. PubMed ID: 8922662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The successful development of bisphosphonates in the therapy of osteoporosis].
    Fassbender WJ; Stumpf UC; Kurth A
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects of bisphosphonates: implications for osteoporosis management.
    Kennel KA; Drake MT
    Mayo Clin Proc; 2009 Jul; 84(7):632-7; quiz 638. PubMed ID: 19567717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quarterly intravenous ibandronate for postmenopausal osteoporosis.
    Emkey RD
    Womens Health (Lond); 2008 May; 4(3):219-28. PubMed ID: 19072470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of highly potent bisphosphonates in the treatment of osteoporosis.
    McClung M
    Curr Osteoporos Rep; 2003 Dec; 1(3):116-22. PubMed ID: 16036074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
    Reginster JY
    Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bisphosphonates in osteoporosis therapy. Standards and perspectives].
    Reinsdorf S; Habermann B; Hochmuth K; Kurth AA
    Orthopade; 2007 Feb; 36(2):110-7. PubMed ID: 17252258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for the prevention and treatment of osteoporosis.
    Maraka S; Kennel KA
    BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
    Papapoulos SE; Schimmer RC
    Ann Rheum Dis; 2007 Jul; 66(7):853-8. PubMed ID: 17277001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY
    Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
    Soen S
    Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress and problems in oral bisphosphonate].
    Takeuchi Y
    Clin Calcium; 2014 Jan; 24(1):27-33. PubMed ID: 24369277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate therapy for secondary osteoporosis: adult perspective.
    Reid IR
    Horm Res Paediatr; 2011; 76 Suppl 1():28-32. PubMed ID: 21778745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.